Vaccine safety: Current systems and recent findings

Current Opinion in Pediatrics

Volumn 22, Issue 1, 2010, Pages 88-93

  Wharton, Melinda ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Immuization; Pharmacoepidemiology; Postlicensure surveillance; Vaccine safety; Vaccines

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; PERTUSSIS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; YELLOW FEVER VACCINE;

ACUTE BRAIN DISEASE; BRAIN DISEASE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEBRILE CONVULSION; GUILLAIN BARRE SYNDROME; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY REACTION; INTUSSUSCEPTION; LICENSING; MENINGITIS; MYOCLONUS EPILEPSY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUBACUTE SCLEROSING PANENCEPHALITIS; SYNCOPE; VACCINATION;

DATABASES AS TOPIC; DRUG APPROVAL; DRUG HYPERSENSITIVITY; HEALTH POLICY; HUMANS; IMMUNOCOMPROMISED HOST; MEDICATION ERRORS; PRODUCT SURVEILLANCE, POSTMARKETING; SAFETY; VACCINATION; VACCINES; VACCINES, ATTENUATED;

EID: 75749145932     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3283350425     Document Type: Review

References (49)

1. CDC. Recommended immunization schedules for persons aged 0 through 18 years-United States, 2010. Morbid Mortal Wkly Report (in press).
2. CDC. Recommended adult immunization schedule-United States, 2010. Morb Mortal Wkly Rep (in press).
3. Ellenberg SS, Foulkes MA, Midthun K, Goldenthal KL. Evaluating the safety of new vaccines:summary of a workshop. AmJ Public Health 2005; 95:800-807.
4. Ellenberg SS. Safety considerations for new vaccine development. Pharmacoepidemiol Drug Safety 2001; 10:411-415.
5. Iskander J, Pool V, Zhou W, et al. Data mining in the U. S. using the Vaccine Adverse Event Reporting System. Drug Safety 2006; 29:375-384.
6. Varricchio F, Iskander J, DeStefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23:287-294. (Pubitemid 38508877)
7. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. AmJ Public Health 1995; 85:1706-1709.
8. CDC. Intussusception among recipients of rotavirus vaccine: United States, 1998-1999. Morb Mortal Wkly Rep 1999; 48:577-581.
9. CDC. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, June 2005-September 2006. Morb Mortal Wkly Rep 2006; 55:1120-1124.
10. Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 2009, doi:10. 1016/S0140-6736(09)61877-61878 [Epub ahead of print]
11. CDC. Imported vaccine-associated paralytic poliomyelitis-United States, 2005. Morb Mortal Wkly Rep 2006; 55:97-99.
12. Alexander JP, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009; 199:391-397.
13. ChavesSS, Haber P, Walton K, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the Vaccine Adverse Event Reporting System, 1995-2005. J Infect Dis 2008; 197 (Suppl 2):S170-S177.
14. Bonnet MC, Dutta A, Weinberger C, Plotkin SA. Mumps vaccine virus strains and aseptic meningitis. Vaccine 2006; 24:7037-7045.
15. Bellini WJ, Rota JS, Loew JE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis 2005; 192:1686-1693.
16. Rue-Cover A, Iskander J, Lyn S, et al. Death and serious illness following influenza vaccination: a multidisciplinary investigation. Pharmacoepidemiol Drug Saf 2009; 18:504-511.
17. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-572.
18. Nathanson N, Langmuir AD. The Cutter incident: poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. Am J Hyg 1963; 78:29-60.
19. Shui IM, Shi P, Dutta-Linn MM, et al. Predictive value of seizure ICD-9 codes for vaccine safety research. Vaccine 2009; 27:5307-5312.
20. DeStefano F. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Safety 2001; 10:403-406.
21. DeStefano F, Tokars J. H1N1 vaccine safety monitoring: beyond background rates. Lancet 2009, doi:10. 1016/S0140-6736(09)61917-61926 [Epub ahead of print]
22. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Medical Care 2007; 45:S89-S95.
23. CDC. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. Morb Mortal Wkly Rep 2008; 57:258-260.
24. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656-4661.
25. Yih WK, Nordin JD, Mulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 2009; 27:4257-4262.
26. CDC. Withdrawal of rotavirus vaccine recommendation. Morb Mortal Wkly Rep 1999; 48:1007.
27. Ruiz-Palacios GM, Pé rez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New Engl J Med 2006; 354:11-22.
28. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl J Med 2006; 354:23-33. (Pubitemid 43048948)
29. Haber P, Patel M, Izurieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008; 121:1206-1212.
30. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112:815-820.
31. Wood RA, Berger M, Dreskin SC, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 2008; 122:e771-e777.
32. CDC. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2006; 55:1-48.
33. CDC. Syncope after vaccination-United States, January 2005-July 2007. Morb Mortal Wkly Rep 2008; 57:457-460.
34. Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med 1997; 151:255-259.
35. Woo EJ, Ball R, Braun MM. Fatal syncope-related fall after immunization. Arch Pediatr Adolesc Med 2005; 159:1083.
36. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 750-757.
37. American Academy of Pediatrics. Active immunization. In: Pickering LK, editor. 2006 Red Book: Report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
38. Miller ER, Hibbs BF, Slade BA. Vaccine administration errors reported to the Vaccine Adverse Event Reporting System, 2008 National Immunization Conference Presentation. http://cdc. confex. com/cdc/nic2008/webprogram/ Paper15568. html.
39. CDC. Inadvertent intradermal administration of tetanus toxoid-containing vaccines instead of tuberculosis skin tests. Morb Mortal Wkly Rep 2004; 53:662, 664.
40. Chang S, Pool V, O'Connell K, et al. Preventable mix-ups of tuberculin and vaccines. Drug Safety 2008; 31:1027-1033.
41. CDC. Unintentional administration of varicella virus vaccine-United States, 1996. Morb Mortal Wkly Rep 1996; 45:1017-1018.
42. Poland GA, Ovsyannikova IG, Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J 2009; 28: 431-432.
43. Ball R, Shadomy SV, Meyer A, et al. HLA type and immune response to Borrelia bergdorferi outer surface protein A in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum 2009; 60: 1179-1186.
44. Stanley SL, Frey SE, Taillon-Miller P, et al. The immunogenetics of smallpox vaccination. J Infect Dis 2007; 196:212-219.
45. Reif DM, McKinney BA, Motsinger AA, et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis 2008; 198:16-22.
46. Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SNC1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 2006; 5:488-492.
47. Mizukami T, Imai J, Hamaguchi I, et al. Application of DNA microarray technology to influenza A/Vietnam/1194/2004. Vaccine 2008; 26:2270-2283.
48. Mosca F, Tritto E, Monaci E, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008; 105:10501-10506.
49. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116-125.